San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Cytovale is raising $8,433,479.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ajay Shah played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cytovale

Cytovale, based in San Francisco, Calif., is a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, and applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes. We’re a team of biologists, data scientists, and engineers developing mechanical biomarkers to improve human health. Our novel microfluidic platform allows us to probe individual cells to quantify the mechanical signatures of disease. We are applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes and reduces treatment cost.

To learn more about Cytovale, visit http://cytovale.com/

Contact:
Ajay Shah, Chief Executive Officer
562-881-6919
ajay.shah@cytovale.com
https://www.linkedin.com/in/ajaymukeshshah/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved